Literature DB >> 12411421

The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia.

Constanze R Scherer1, Christian Lerche, Niels Decher, Adrienne T Dennis, Patrick Maier, Eckhard Ficker, Andreas E Busch, Bernd Wollnik, Klaus Steinmeyer.   

Abstract

1. The human HERG gene encodes the cardiac repolarizing K(+) current I(Kr) and is genetically inactivated in inherited long QT syndrome 2 (LQTS2). The antihistamine terfenadine blocks HERG channels, and can cause QT prolongation and torsades de pointes, whereas its carboxylate fexofenadine lacks HERG blocking activity. 2. In the present study the ability of fexofenadine to block the K897T HERG channel variant was investigated. The underlying single nucleotide polymorphism (SNP) A2960C was identified in a patient reported to develop fexofenadine-associated LQTS. 3. K897T HERG channels produced wild-type-like currents in Xenopus oocytes. Even at a concentration of 100 micro M, fexofenadine did not inhibit wild-type or K897T HERG channels. Coexpression of wild-type and K897T HERG with the ss-subunit MiRP1, slightly changed current kinetics but did not change sensitivity to terfenadine and fexofenadine. 4. Western blot analysis and immunostaining of transiently transfected COS-7 cells demonstrated that overall expression level, glycosylation pattern and subcellular localization of K897T HERG is indistinguishable from wild-type HERG protein, and not altered in the presence of 1 micro M fexofenadine. 5. We provide the first functional characterization of the K897T HERG variant. We demonstrated that K897T HERG is similar to wild-type HERG, and is insensitive to fexofenadine. Although the polymorphism changes PKA and PKC phosphorylation sites, regulation of K897T HERG by these kinases is not altered. 6. Our results strongly indicate that QT lengthening and cardiac arrhythmia in the reported case of drug-induced LQT are not due to the K897T exchange or to an inhibitory effect of fexofenadine on cardiac I(Kr) currents. British Journal of

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411421      PMCID: PMC1573545          DOI: 10.1038/sj.bjp.0704873

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  QT lengthening and arrhythmias associated with fexofenadine.

Authors:  T Giraud
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

2.  Fexofenadine-induced QT prolongation: a myth or fact?

Authors:  S Dhar; P K Hazra; S Malakar; G Mistri
Journal:  Br J Dermatol       Date:  2000-06       Impact factor: 9.302

3.  Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity.

Authors:  C Lerche; C R Scherer; G Seebohm; C Derst; A D Wei; A E Busch; K Steinmeyer
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

4.  Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites.

Authors:  J P Lees-Miller; Y Duan; G Q Teng; H J Duff
Journal:  Mol Pharmacol       Date:  2000-02       Impact factor: 4.436

Review 5.  [Drug-induced long QT syndrome and torsade de pointes arrhythmias].

Authors:  S Dhein
Journal:  Dtsch Med Wochenschr       Date:  2000-06-02       Impact factor: 0.628

6.  A common polymorphism associated with antibiotic-induced cardiac arrhythmia.

Authors:  F Sesti; G W Abbott; J Wei; K T Murray; S Saksena; P J Schwartz; S G Priori; D M Roden; A L George; S A Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

7.  A structural basis for drug-induced long QT syndrome.

Authors:  J S Mitcheson; J Chen; M Lin; C Culberson; M C Sanguinetti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

8.  Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome.

Authors:  E Ficker; D Thomas; P C Viswanathan; A T Dennis; S G Priori; C Napolitano; M Memmi; B A Wible; E S Kaufman; S Iyengar; P J Schwartz; Y Rudy; A M Brown
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-10       Impact factor: 4.733

9.  Survey of the coding region of the HERG gene in long QT syndrome reveals six novel mutations and an amino acid polymorphism with possible phenotypic effects.

Authors:  P Laitinen; H Fodstad; K Piippo; H Swan; L Toivonen; M Viitasalo; J Kaprio; K Kontula
Journal:  Hum Mutat       Date:  2000-06       Impact factor: 4.878

10.  Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine.

Authors:  M Taglialatela; A Pannaccione; P Castaldo; G Giorgio; L Annunziato
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

View more
  15 in total

1.  Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine.

Authors:  So-Young Lee; Young-Jin Kim; Kyong-Tai Kim; Han Choe; Su-Hyun Jo
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

Review 2.  Modification of K+ channel-drug interactions by ancillary subunits.

Authors:  Glenna C L Bett; Randall L Rasmusson
Journal:  J Physiol       Date:  2007-12-20       Impact factor: 5.182

3.  Modulation of Ether-à-Go-Go Related Gene (ERG) Current Governs Intrinsic Persistent Activity in Rodent Neocortical Pyramidal Cells.

Authors:  Edward D Cui; Ben W Strowbridge
Journal:  J Neurosci       Date:  2017-11-24       Impact factor: 6.167

4.  Blockade of HERG cardiac K+ current by antifungal drug miconazole.

Authors:  Kan Kikuchi; Toshihisa Nagatomo; Haruhiko Abe; Kazunobu Kawakami; Henry J Duff; Jonathan C Makielski; Craig T January; Yasuhide Nakashima
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

Review 5.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy.

Authors:  Kazunobu Kawakami; Toshihisa Nagatomo; Haruhiko Abe; Kan Kikuchi; Hiroko Takemasa; Blake D Anson; Brian P Delisle; Craig T January; Yasuhide Nakashima
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

Review 7.  KCNE2 and the K (+) channel: the tail wagging the dog.

Authors:  Geoffrey W Abbott
Journal:  Channels (Austin)       Date:  2012-01-01       Impact factor: 2.581

8.  Allocryptopine and benzyltetrahydropalmatine block hERG potassium channels expressed in HEK293 cells.

Authors:  Kun Lin; Yu-qi Liu; Bin Xu; Jin-liao Gao; Yi-cheng Fu; Yu Chen; Qiao Xue; Yang Li
Journal:  Acta Pharmacol Sin       Date:  2013-03-25       Impact factor: 6.150

9.  Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen.

Authors:  Dierk Thomas; Bernd Gut; Syrus Karsai; Anna-Britt Wimmer; Kezhong Wu; Gunnar Wendt-Nordahl; Wei Zhang; Sven Kathöfer; Wolfgang Schoels; Hugo A Katus; Johann Kiehn; Christoph A Karle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-06-25       Impact factor: 3.000

10.  Functional significance of KCNH2 (HERG) K897T polymorphism for cardiac repolarization assessed by analysis of T-wave morphology.

Authors:  Eeva H Linna; Juha S Perkiömäki; Mari Karsikas; Tapio Seppänen; Markku Savolainen; Y Antero Kesäniemi; Timo Mäkikallio; Heikki V Huikuri
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-01       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.